ATE395054T1 - Pharmazeutische zusammensetzungen enthaltend fluorierte oder perfluorierte carboxylsäuren - Google Patents

Pharmazeutische zusammensetzungen enthaltend fluorierte oder perfluorierte carboxylsäuren

Info

Publication number
ATE395054T1
ATE395054T1 AT02712094T AT02712094T ATE395054T1 AT E395054 T1 ATE395054 T1 AT E395054T1 AT 02712094 T AT02712094 T AT 02712094T AT 02712094 T AT02712094 T AT 02712094T AT E395054 T1 ATE395054 T1 AT E395054T1
Authority
AT
Austria
Prior art keywords
perfluorized
pharmaceutical compositions
carboxylic acids
compositions containing
containing fluorinated
Prior art date
Application number
AT02712094T
Other languages
English (en)
Inventor
Clifford Elcombe
Charles Wolf
Original Assignee
Cxr Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cxr Biosciences Ltd filed Critical Cxr Biosciences Ltd
Application granted granted Critical
Publication of ATE395054T1 publication Critical patent/ATE395054T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
AT02712094T 2001-02-16 2002-02-18 Pharmazeutische zusammensetzungen enthaltend fluorierte oder perfluorierte carboxylsäuren ATE395054T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0103809.0A GB0103809D0 (en) 2001-02-16 2001-02-16 Methods

Publications (1)

Publication Number Publication Date
ATE395054T1 true ATE395054T1 (de) 2008-05-15

Family

ID=9908862

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02712094T ATE395054T1 (de) 2001-02-16 2002-02-18 Pharmazeutische zusammensetzungen enthaltend fluorierte oder perfluorierte carboxylsäuren

Country Status (13)

Country Link
US (2) US8487003B2 (de)
EP (3) EP2260842A2 (de)
JP (2) JP4652665B2 (de)
AT (1) ATE395054T1 (de)
AU (3) AU2002232001B2 (de)
CA (2) CA2737095A1 (de)
CY (1) CY1108262T1 (de)
DE (1) DE60226575D1 (de)
DK (1) DK1359906T3 (de)
ES (1) ES2309153T3 (de)
GB (2) GB0103809D0 (de)
PT (1) PT1359906E (de)
WO (1) WO2002066028A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220045D0 (en) * 2002-08-29 2002-10-09 Cxr Biosciences Ltd Sc 211745 Methods
SG172784A1 (en) * 2009-01-02 2011-08-29 Fournier Lab Ireland Ltd Novel use of fibrates
US20120219596A1 (en) 2009-07-30 2012-08-30 Wendelin Stark Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
GB201002861D0 (en) 2010-02-19 2010-04-07 Cxr Biosciences Ltd Compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2567011A (en) 1949-01-10 1951-09-04 Minnesota Mining & Mfg Fluorocarbon acids and derivatives
US4624851A (en) * 1983-04-22 1986-11-25 Elena Avram Treatment of symptoms of neoplastic diseases
DE4040619A1 (de) * 1990-12-19 1992-06-25 Boehringer Mannheim Gmbh Neue aliphatische amide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5621144A (en) 1991-11-29 1997-04-15 Isis Innovation Limited Fluorinated compounds as oxygen transport agents
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6013795A (en) 1996-11-04 2000-01-11 3M Innovative Properties Company Alpha-branched fluoroalkylcarbonyl fluorides and their derivatives
US6015838A (en) 1996-11-04 2000-01-18 3M Innovative Properties Company Aqueous film-forming foam compositions
CA2337690C (en) 1998-07-27 2013-10-01 Texas Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
GB9917405D0 (en) 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
GB0220045D0 (en) 2002-08-29 2002-10-09 Cxr Biosciences Ltd Sc 211745 Methods
US6875060B2 (en) 2002-10-21 2005-04-05 Adc Telecommunications, Inc. High density patching system

Also Published As

Publication number Publication date
GB0103809D0 (en) 2001-04-04
EP1359906A2 (de) 2003-11-12
WO2002066028A3 (en) 2002-11-14
EP1745779A3 (de) 2011-05-04
ES2309153T3 (es) 2008-12-16
US8487003B2 (en) 2013-07-16
EP1359906B1 (de) 2008-05-14
CY1108262T1 (el) 2014-02-12
AU2002232001B2 (en) 2006-06-29
US20050175639A1 (en) 2005-08-11
CA2737095A1 (en) 2002-08-29
GB2383535B (en) 2005-09-21
US20120029079A1 (en) 2012-02-02
JP4652665B2 (ja) 2011-03-16
CA2438085A1 (en) 2002-08-29
AU2006222766B2 (en) 2009-08-06
GB0203716D0 (en) 2002-04-03
CA2438085C (en) 2011-05-03
WO2002066028A2 (en) 2002-08-29
AU2009233689A1 (en) 2009-11-26
DK1359906T3 (da) 2008-09-15
DE60226575D1 (de) 2008-06-26
JP2004531482A (ja) 2004-10-14
AU2006222766A1 (en) 2006-11-02
JP2009132726A (ja) 2009-06-18
GB2383535A (en) 2003-07-02
EP2260842A2 (de) 2010-12-15
EP1745779A2 (de) 2007-01-24
PT1359906E (pt) 2008-08-26

Similar Documents

Publication Publication Date Title
RU2159761C2 (ru) Замещенные 4-биарилмасляные или 5-биарилпентановые кислоты или их производные, способы их получения, фармацевтическая композиция и способ лечения
DE60207234D1 (de) Verfahren zur herstellung einer gereinigten shilajit-zusammensetzung aus nativem shilajit
DE60000235D1 (de) Mittel insbesondere für Kosmetika enthaltend eine Sapogenin
NO991635L (no) Farmas°ytisk preparat omfattende eikospentaensyre og/eller stearidonsyre
ATE355056T1 (de) Jasmonate enthaltende therapeutische zusammensetzungen für die behandlung von krebs
EP1690536A3 (de) Verwendung von r-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxy-methyl-Phenylisobuttersäureester Hydrogenfumarat zur Behandlung von Harndrang-Inkontinenz und anderen spasmogenen Leiden
DE60034919D1 (de) Kosmetische Zubereitung Ester hydroxylierter Fettsäuren enthaltend
CY1108262T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν φθοριωμενα ή υπερφθοριωμενα καρβοξυλικα οξεα
BR9402558A (pt) Compostos, processo para sua preparação, composições farmacêuticas e uso dos compostos
FR2792191B1 (fr) Composition cosmetique comprenant l'association d'un ester particulier et d'un compose silicone
DE60022188D1 (de) Amorphe salpetersäureester und deren pharmazeutische zusammensetzungen
MA27031A1 (fr) Composition pharmaceutique comprenant un inhibiteur de lipase et un ester d'acide gras de saccharose
AU7448694A (en) Inclusion complex
BR0208275A (pt) Composições farmacêuticas para tratamento de arteriosclerose
BR0116835A (pt) Composição e processo
ATE360027T1 (de) 11beta-langkettig-substituierte estratriene, verfahren zur herstellung, pharmazeutische präparate, die diese 11beta-langkettig- substituierten estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
AU2002342498A1 (en) Organic compounds
DE60204681D1 (de) Verfahren zur herstellung von 2-[4-(2,2,-dihalocyclopropyl)phenoxy]-alkansäuren und ihre estern
DE69108580D1 (de) Optisch aktives Derivat der d-2-(6-Methoxy-2-naphthyl)-propionsäure und es enthaltende pharmazeutische Zusammensetzungen.
AR011476A1 (es) Nitrometilcetonas, su procedimiento de preparacion, composiciones que las contienen y su utilizacion para preparar medicamentos.
DE60022229D1 (de) Benzoesäureester und flüssigkristallmedium
Neves Insights on the biodegradation of acrylic reline resins
ES2104193T3 (es) Procedimiento para la preparacion de acidos 4,5-difluoro-benzoicos, derivados de acidos 4,5-difluoro-benzoicos y 4,5-difluoro-benzaldehidos.
FR2834214B1 (fr) Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
ATE245621T1 (de) (+)- und (-)-2-cyclododecylpropanol und (+)- und (-)-2-cyclododecylpropionsäure sowie deren herstellung und verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1359906

Country of ref document: EP